HPV Type 31: A Comprehensive Guide to Risks, Symptoms, and Protection

Table of Contents

• What is HPV Type 31?
• Transmission and Symptoms
• HPV 31 and Cancer Risk
• Testing and Diagnosis
• Treatment and Management
• Prevention and Vaccination
• Frequently Asked Questions

Human Papillomavirus (HPV) is the most common sexually transmitted infection globally, with over 200 identified types. Among these, a subset is classified as "high-risk" due to their potential to cause cancer. HPV type 31 is one such high-risk strain, belonging to the same family as the more widely known types 16 and 18. Understanding HPV type 31 is crucial for proactive sexual health, as knowledge empowers prevention, early detection, and effective management. This comprehensive guide will delve into what makes HPV 31 distinct, its connection to cervical and other cancers, the latest research on vaccination efficacy, and practical steps you can take to protect your health. Whether you're seeking information after a diagnosis or looking to bolster your preventive knowledge, this article provides the expert, judgment-free insights you need.

What is HPV Type 31? Understanding the High-Risk Category

HPV type 31 is an alphapapillomavirus classified within species 9 (Alpha-9), a group that includes other high-risk types like HPV 16, 33, 35, 52, and 58. This classification is significant because viruses within the same species share genetic similarities and often similar carcinogenic potential. Unlike low-risk HPV types that cause benign genital warts, high-risk types like HPV 31 can lead to cellular changes that, if persistent, may progress to cancer over many years.

The virus infects epithelial cells in the mucosal surfaces of the cervix, anus, vagina, vulva, penis, and oropharynx (throat). Its oncogenic (cancer-causing) potential stems from the activity of two viral proteins, E6 and E7, which interfere with critical tumor suppressor proteins in human cells (p53 and pRb, respectively). This interference can disrupt the normal cell cycle, leading to uncontrolled cell growth and accumulation of DNA damage.

"While HPV 16 and 18 are responsible for the majority of HPV-related cancers, it's vital not to overlook other high-risk types in the Alpha-9 species, like HPV 31 and 33. Their collective contribution to cervical cancer burden is substantial, which is why broad-spectrum vaccination is a cornerstone of cancer prevention." – Illustrative expert opinion based on virology principles.

HPV 31 in Global Prevalence Studies

Global meta-analyses help us understand the footprint of different HPV types. A landmark 2010 study by Bruni et al., which analyzed data from over 1 million women with normal cytology, provided crucial insights into the worldwide prevalence of various HPV types. While HPV 16 was consistently the most common, other high-risk types, including those in the Alpha-9 species like HPV 31, showed significant regional variation in prevalence. This underscores that HPV type 31 is a globally relevant pathogen, not a rare anomaly.

Transmission and Symptoms of HPV Type 31

Transmission of HPV type 31 occurs primarily through intimate skin-to-skin contact, most commonly during vaginal, anal, or oral sex. It's important to emphasize that penetration is not required for transmission. The virus can infect areas not covered by a condom, so while condoms reduce risk, they do not eliminate it entirely.

A defining and challenging characteristic of high-risk HPV infections, including HPV 31, is their asymptomatic nature. The infection itself does not cause pain, itching, or visible signs like warts. This "silent" progression is why regular screening is non-negotiable for early detection of the cellular changes the virus can induce.

• Primary Transmission Route: Sexual contact (vaginal, anal, oral).
• Key Fact: Most sexually active individuals will contract some form of HPV in their lifetime, but most infections are cleared by the immune system within 1-2 years.
• No Symptoms: The high-risk infection itself has no visible symptoms. The concern is the long-term cellular damage it may cause.
• Vertical Transmission: Rarely, a mother can transmit HPV to an infant during childbirth, potentially leading to recurrent respiratory papillomatosis.

HPV 31 and Cancer Risk: What the Research Shows

HPV type 31 is unequivocally classified as a high-risk, carcinogenic type by the International Agency for Research on Cancer (IARC). Persistent infection with this virus is a necessary cause of nearly all cervical cancers and is implicated in a significant proportion of other anogenital and oropharyngeal cancers.

While HPV 16 is the dominant player, responsible for about 50-60% of cervical cancers, and HPV 18 for another 10-15%, the remaining cases are attributed to other high-risk types. Collectively, the five most common next-in-line types (31, 33, 45, 52, 58) account for an additional 15-20% of cervical cancer cases globally. This makes understanding and screening for HPV type 31 a critical component of comprehensive cancer prevention.

Recent research continues to refine our understanding of risk stratification among non-16/18 types. A 2023 study by Purut et al. asked "Could HPV Type 33 Be More Risky Than We Thought?" This kind of research highlights the ongoing scientific effort to rank the oncogenic potential of types like 31 and 33 more precisely, which can inform clinical management guidelines for patients who test positive for these strains.

Testing and Diagnosis for HPV Type 31

Diagnosis of an HPV type 31 infection is not based on symptoms but on specific laboratory tests. The landscape of cervical screening has evolved from primarily Pap smears (cytology) to include more sensitive HPV DNA testing.

Primary HPV Testing

This is increasingly becoming the first-line screening method in many countries. The test detects the presence of DNA from high-risk HPV types in a sample of cervical cells. Many modern tests are genotype-specific, meaning they can identify if HPV 16 or 18 is present, and then pool the result for a group of "other high-risk types," which includes HPV 31, 33, 45, 52, 58, etc. Some advanced assays can provide full genotyping, specifying exactly which type (like 31) is present.

Cytology (Pap Smear)

The Pap smear examines cervical cells under a microscope for abnormal changes (dysplasia). It can detect the cellular consequences of an HPV infection but cannot identify the specific HPV type causing those changes. An abnormal Pap result often triggers an HPV test to determine the next steps.

Co-testing and Management

Guidelines vary, but a common pathway is:
1. Positive for "Other High-Risk HPV" (like HPV 31) with a normal Pap: Usually means repeat co-testing in 1 year, as the immune system may clear the infection.
2. Positive for HPV (any high-risk type) with an abnormal Pap: Typically leads to a colposcopy, a procedure to closely examine the cervix and take biopsies if needed.

"A positive test for a high-risk HPV type like 31 is not a diagnosis of cancer. It's a risk indicator. The vast majority of these infections will clear on their own. Our role is to monitor carefully to identify the small percentage where the infection persists and causes pre-cancerous changes, which are highly treatable." – Illustrative expert opinion based on clinical management guidelines.

Treatment and Management of an HPV 31 Infection

It is critical to understand: There is no medical treatment to cure the HPV virus itself. The focus of management is on treating the health problems HPV causes, namely pre-cancerous cell changes (lesions).

Condition	Typical Management Approach	Goal
HPV Infection Only (No cell changes)	Watchful waiting with repeat testing (e.g., in 1 year). The body's immune system is the primary "treatment."	Monitor for clearance of the virus.
Low-Grade Lesions (CIN 1 / LSIL)	Often monitored, as many regress spontaneously. Treatment may be considered if persistent.	Prevent progression.
High-Grade Lesions (CIN 2/3 / HSIL)	Excisional treatment (e.g., LEEP, Cone Biopsy) or ablative treatment (e.g., cryotherapy).	Remove abnormal cells to prevent invasive cancer.
Genital Warts (caused by low-risk types)	Topical medications, cryotherapy, surgical removal. Note: HPV 31 does not cause warts.	Remove visible warts.

Lifestyle factors that support a robust immune system—such as a balanced diet, regular exercise, not smoking, and managing stress—are universally recommended. Smoking, in particular, is a major co-factor that significantly increases the risk of an HPV infection progressing to cancer.

Prevention and Vaccination: Your Best Defense Against HPV 31

Prevention of HPV type 31 infection is highly effective thanks to prophylactic HPV vaccines. These vaccines are not therapeutic (they do not treat existing infections) but are exceptionally effective at preventing new infections with the types they cover.

The Power of HPV Vaccination

All currently available HPV vaccines—Gardasil 9, Gardasil 4, and Cervarix—protect against HPV type 31.

• Gardasil 9 (9-valent): Protects against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58. This is the most comprehensive vaccine, covering the seven highest-risk types and the two causing most warts.
• Gardasil 4 (4-valent): Protects against 6, 11, 16, 18.
• Cervarix (2-valent): Protects against 16 and 18.

Due to cross-protection—where protection against one type offers some protection against genetically similar types—even the 2-valent vaccine provides partial protection against HPV 31. However, the 9-valent vaccine offers direct and robust protection.

A 2024 review by Hampson et al. on the effects of prophylactic HPV vaccines confirms their dramatic impact. The study notes that vaccination has led to significant decreases in the prevalence of vaccine-type HPV infections and associated pre-cancerous lesions in vaccinated populations. This real-world evidence solidifies vaccination as a public health triumph against cervical and other HPV-related cancers.

Other preventive measures include consistent and correct condom use (which reduces but doesn't eliminate risk) and mutual monogamy with an uninfected partner. For those who are sexually active, adhering to recommended cervical screening schedules is an essential form of secondary prevention, allowing for early intervention.

Frequently Asked Questions About HPV Type 31

Is HPV type 31 an STD?

Yes, HPV type 31 is a sexually transmitted infection (STI). It is spread through intimate skin-to-skin contact, most commonly during vaginal, anal, or oral sex.

Does HPV 31 go away?

Can men get tested for HPV type 31?

How can I support my health if I test positive?